CHMP recommendations include Ajovy, Vizimpro, Humira biosimilars

EMA's CHMP recommended a basket of approvals and label extensions on Friday, including Ajovy fremanezumab, Vizimpro dacomitinib and two Humira biosimilars. CHMP also backed an expanded label for Forxiga dapagliflozin to include Type I diabetes.

The agency recommended Ajovy from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) to prevent migraine. FDA approved the mAb targeting the CGRP ligand in September...